Do you work with patients or clients with cognitive impairment? Visit our new online portal for free clinical practice tools, training materials, and other resources for physicians, nurses, social workers, and other professionals.
Older adults who take anticholinergic drugs, which are commonly prescribed for a wide range of health conditions, may be at significantly higher risk of developing dementia—and the greater the use of the drugs, the higher the potential risk. The NIA-supported findings appeared online Jan. 26, 2015, in JAMA Internal Medicine.
Researchers have long wondered why some older people remain cognitively normal despite having abnormal levels of beta-amyloid in their brains, a hallmark of Alzheimer’s disease. While research has shown that older adults with Mild Cognitive Impairment (MCI), which often leads to Alzheimer’s, frequently have increased activity in the hippocampus compared to their cognitively healthy peers, scientists questioned what the hyperactivity represented. Was it helping to compensate for declining brain function or signaling onset of the disease?
Many people who have been affected by Alzheimer’s wonder how they can help combat this devastating disease. Volunteering to participate in research is one powerful way. Right now, at least 70,000 volunteers are needed for more than 150 active Alzheimer’s and related clinical trials and studies in the United States. All kinds of people, including healthy older adults, can join in this critical research.
Training to improve cognitive abilities in older people lasted to some degree 10 years after the training program was completed, according to results of a randomized clinical trial supported by the National Institutes of Health.
The findings showed training gains for aspects of cognition involved in the ability to think and learn, but researchers said memory training did not have an effect after 10 years.
Evaluating the cognitive status of older patients in the primary care setting is one of the first steps in determining the cause of problems with memory, attention, and other aspects of thinking that can affect their health and well-being. With dozens of instruments available, finding the right ones to use can be a challenge. Now, clinicians and researchers have a new and simple way to find appropriate instruments—through a searchable database from the National Institute on Aging (NIA) at the National Institutes of Health.
A randomized clinical trial of estrogen therapy in younger postmenopausal women, aged 50–55, has found no long-term risk or benefit to cognitive function. The National Institutes of Health-supported study, reported in JAMA Internal Medicine on June 24, 2013, looked at women taking conjugated equine estrogens, the most common type of postmenopausal hormone therapy in the United States.
The earlier Women’s Health Initiative Memory Study (WHIMS) linked the same type of hormone therapy to cognitive decline and dementia in older postmenopausal women.